Opinions+

Neurotransmissions Jason Karlawish

STAT Plus: The word ‘dementia’ is about to lose its value

The Workup Vishal Khetpal

STAT Plus: Why this cardiologist is cautious about the Apple Watch’s blood pressure feature

Opinions+ Elise Felicione

STAT Plus: 5 things to consider to bring ambient digital scribes to clinical research

Opinions+ Gillian Woollett

STAT Plus: Onshoring could threaten the resilient supply chain for biosimilars and generics

Opinions+ Jeffrey Francer and Victor Cruz

STAT Plus: Lilly executives: How the FDA’s new PreCheck program can unleash the future of U.S. medicine manufacturing

Neurotransmissions Jason Karlawish

STAT Plus: The way we talk about dementia is about to change completely

Lab Dish Paul Knoepfler

STAT Plus: Despite the drama and hype from influencers, longevity science is making real progress

Opinions+ David Grainger

STAT Plus: Why pharma companies are suddenly pausing investment in the U.K.

The Workup Vishal Khetpal

STAT Plus: Make statins available without a prescription

Opinions+ Olivier Elemento, Cora N. Sternberg, and Sean Khozin

STAT Plus: Why Silicon Valley should demand clinical trials for its medical AI

Opinions+ Sasha Ebrahimi and Milan Mrksich

STAT Plus: The future of medicine lies in multifunctional therapies

Opinions+ Naomi Schwartz and Axel Wirth

STAT Plus: The FDA’s absence from international standards meetings threatens U.S. leadership

Lab Dish Paul Knoepfler

STAT Plus: Japan’s green light for making human embryos from stem cells takes us into uncharted territory

Opinions+ Hamid Tizhoosh

STAT Plus: I’ve spent 30 years trying to harness AI to fight cancer. I’m dismayed by the AI pseudo-revolution

Opinions+ Yvonne Greenstreet

Alnylam CEO: Congress must pass the MINI Act to protect future biotech breakthroughs

Lab Dish Paul Knoepfler

STAT Plus: RFK Jr.’s FDA may take cues on stem cells from red-state laws, clinic doctors

Opinions+ Amin Rostami-Hodjegan

STAT Plus: The end of animal testing? Transitioning to models is promising — but no silver bullet

Opinions+ Peter Bonis

STAT Plus: 11 lessons for health tech startups from one of UpToDate’s creators

Opinions+ Soumi Saha and Somaieh McMullan

STAT Plus: How to evaluate GLP-1s and Medicare costs? Here’s one idea

Opinions+ Stephen J. Ubl

STAT Plus: PhRMA CEO: ‘Most-favored nation’ policy isn’t the way to lower drug prices

Opinions+ Kevin A. Schulman and Wasan Kumar

STAT Plus: Health care costs: one of the biggest obstacles to reshoring American industry

First Opinion Richard Mackey and Chinmoy Barua

STAT Plus: AI-powered nudges for chronic disease care need emotional intelligence

Opinions+ Brendan Frey

STAT Plus: Deep Genomics founder: Why AI for drug discovery will far exceed current expectations

Opinions+ Sahand Hormoz

STAT Plus: Don’t cut NIH and NSF budgets — let the government invest like a venture capitalist

Opinions+ Chris Gibson

STAT Plus: Recursion CEO: Biotech’s rainy season is not over — but we must race ahead

Opinions+ Karl M. Thompson

STAT Plus: HBCUs can help create a 21st-century bioeconomy and the talent pipeline it requires

Opinions+ Brian Finrow and Sandeep Patel

STAT Plus: 4 ideas to kick-start U.S. drug research — and beat China in biotech

Opinions+ Soraya Bekkali

STAT Plus: The World Health Assembly’s giant leap on rare diseases

Opinions+ Patrick Aguilar and Matt Hoff

STAT Plus: To address the pharmacy crisis, doctors should dispense some drugs